{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088738","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.548446+00:00","generated_at":"2026-05-19T00:35:13.674052+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lineage reports OpRegen 36-month data: +9 ETDRS letters in extensive-coverage GA patients","bullets":["Mean BCVA gain of +6.2 letters (n=10) persisting through 36 months vs. +5.5 at 24 months.","Patients with extensive bleb coverage (n=5) showed mean +9.0 letters at 36 months vs. +7.4 at 24 months.","Retinal structure improvements (RPEDC, ELM) on OCT sustained in treated eyes; untreated fellow eyes declined.","Phase 2a GAlette study enrolling (NCT05626114) testing proprietary surgical delivery devices.","CEO states data challenges view that GA causes irreversible damage; effects durable after single injection."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088738","json":"https://secwatch.observer/filing/0000950170-25-088738.json","markdown":"https://secwatch.observer/filing/0000950170-25-088738.md","text":"https://secwatch.observer/filing/0000950170-25-088738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017025088738/0000950170-25-088738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017025088738/lctx-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T00:35:13.674052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}